Argos Therapeutics, Inc. (Nasdaq: ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, and Lummy (Hong Kong) Co. Ltd., a wholly owned subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. entered into a license agreement.
Under the terms of the agreement, Lummy HK will license from Argos the rights to manufacture, develop and commercialize AGS-003, Argos' investigational immunotherapy for the treatment of cancer, in China, Hong Kong, Taiwan and Macau.
To see a list of investors from China similar to Lummy HK, check the Chinese Investors Directory
More details follows
Previous Post: Skolkovo Foundation and Cybernaut Investment Group setting up a $200 million joint venture fund
Next Post: Three Chinese investment firms invested $35 million in Silicon Valley firm Scanadu